I'm LongbridgeAI, I can summarize articles.TARS.US fell 1.54% this week to close at $78.09, underperforming the S&P 500 by about 1.46 percentage points as the benchmark slipped 0.08%. The daily tape was choppy. Monday (Sep 14) gapped higher and hit a weekly high of $80.24 before settling at $79.95; Tuesday and Wednesday pulled back, with Wednesday printing the weekly low of $77.08; Thursday and Friday then swung between roughly $77.3 and $79.8. The weekly range was just 3.
The Week
TARS.US fell 1.54% this week to close at $78.09, underperforming the S&P 500 by about 1.46 percentage points as the benchmark slipped 0.08%. The daily tape was choppy. Monday (Sep 14) gapped higher and hit a weekly high of $80.24 before settling at $79.95; Tuesday and Wednesday pulled back, with Wednesday printing the weekly low of $77.08; Thursday and Friday then swung between roughly $77.3 and $79.8. The weekly range was just 3.96%, and turnover was light — average daily volume of around 634,000 shares ran about 14% below the 60-day median.
Key Events
The week’s main company-driven story was a deal. On 16 September, reports said Tarsus had agreed to buy Alkeus for $270 million, part of a broader mid-cap biotech consolidation wave. The same day, Novartis and GSK featured in the Fierce Pharma Marketing Awards, though that item is only indirectly relevant to Tarsus as an industry gauge. On 18 September, director William J. Link disclosed the sale of common shares worth about $977,707, with a separate filing showing 12,500 shares sold. There were no material non-routine filings this week; three routine documents were excluded.
Analyst Ratings
Nine brokers cover TARS.US, with eight at buy and one at outperform; there are no hold, underperform or sell ratings. The consensus is strong buy. The consensus target sits at $97.67, about 25.07% above this week’s close of $78.09. The target range runs from $84 to $110, meaning even the low end is above spot. Within the 204-name pharmaceutical peer group, TARS.US ranks 45th by analyst rating, in the upper band.
The Week Ahead
Tarsus has no earnings or corporate calendar entries next week, so the watchlist tilts toward macro. On Tuesday (Sep 22), the Richmond Fed Composite Index lands, with a prior of 4. Wednesday (Sep 23) brings weekly EIA crude and Cushing inventory data, after priors of -0.64 and -0.342. Thursday (Sep 24) is heavier: initial jobless claims, the current account balance, new home sales and EIA natural gas storage. New home sales are forecast at 0.608 versus 0.607 prior. For holders, the key question is whether risk appetite and biotech sector liquidity hold up.
In Short
This week sets up a tension. The M&A signal skews constructive, and the sell-side is firmly positive — consensus strong buy with a target about a quarter above spot. Yet the stock drifted lower on below-median volume, and a director disclosed selling late in the week, a marginal internal signal. Valuation is not cheap either, with a static PB of 9.88x. The follow-through to watch is whether the deal momentum sustains and how insider activity plus macro data shape risk appetite.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.